Flagship Pioneering company Alltrna, which is unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, has appointed Chris Henderson, as chief scientific officer and promoted William (Will) Kiesman, to the post of chief technology officer. 19 August 2023
Privately-held Resolution Therapeutics, a UK biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, has named Amir Hefni as chief executive. 14 August 2023
US adeno-associated virus (AAV) specialist Voyager Therapeutics has announced the appointment of Beth Shafer as chief business officer (CBO). 11 August 2023
San Diego, USAbased cancer specialist Mirati Therapeutics is to replace its chief executive, David Meek, with former CEO Charles Baum taking over on an interim basis. 10 August 2023
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023
San Diego, USA-based cancer focussed biotech Viracta Therapeutics today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect. 7 August 2023
Sino-American biotech specializing in liver disease and cancer Terns Pharmaceuticals has announced that Senthil Sundaram has resigned from his position as Terns’ chief executive for health reasons previously disclosed in January 2022. 5 August 2023
Switzerland-based biologics contract development and manufacturing organization (CDMO), Celonic Group has appointed Dr Samantha Cimitan as chief executive. 3 August 2023
UK-based industry accelerator the Cell and Gene Therapy Catapult (CGT Catapult) today announces that Jeanette Evans has been appointed chief business officer (CBO), taking over from Sharon Brownlow, with effect in August 2023. 1 August 2023
In anticipation of regulatory clearance for its proposed $43 billion acquisition of Seagen, US pharma giant Pfizer today announced a reorganization of its R&D team to create a leading company in the battle against cancer. 27 July 2023
Swiss clinical-stage biotech AC Immune today announced the appointment of Nuno Mendonca as its new chief medical officer of the neurodegenerative diseases specialist. 26 July 2023
Bicara Therapeutics, a biotech start-up founded in 2021 with the goal of developing dual-action biologics, has appointed David Raben as chief medical officer. 24 July 2023
Swiss vaccine company LimmaTech Biologics has in-licensed technology from GSK to continue development and commercialization of a quadrivalent shigellosis vaccine candidate. 20 July 2023
Boston, USA-based biotech start-up Jnana Therapeutics has appointed Dr George Vratsanos as its chief medical officer and head of research and development. 20 July 2023
Brighton, UK-based infectious disease specialist Destiny Pharma today announced that Chris Tovey will join the company as chief executive (CEO) on September 1, 2023. 19 July 2023
UK-based CAR-T therapies specialist Leucid Bio today announced the appointment of Filippo Petti as its chief executive (CEO), with immediate effect. 18 July 2023
Elmar Schnee has been named the new executive chairman of EnteroBiotix, a company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics. 17 July 2023
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024